Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) on Friday, April 11, announced that it has received final approval from the United ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza ...

Zydus Lifesciences has secured final approval from the US Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) tablets in four strengths - 6 mg, 18 mg, 30 mg, and 36 mg.

Zydus Lifesciences share price extended the gains on second day, rising 1 percent in the early trade on April 15 following United States Food and Drug Administration (USFDA) approval for Jaythari ...

Ahmedabad: Pharma major, Zydus Lifesciences Limited has received final approval from the United States Food and Drug ...

The drugmaker has received the USFDA's final approval to manufacture a particular corticosteroid called Deflazacort to treat Duchenne muscular dystrophy.

Jaythari is indicated for the treatment of DMD, a rare and genetic disease that results in ongoing muscle weakness and degeneration.

Stocks like NCL Industries, Persistent Systems, Repco Home Finance, JK Cement, Canara Bank, Union Bank of India, and Yatra ...

Zydus Lifesciences: The company will acquire 85.6% equity shares of Amplitude Surgical SA, France, at a price of Euro 6.25 ...

Explore the latest stock alerts: Macrotech, Reliance, Vedanta, Dr Reddy's, and more. Check out key developments today!

Zydus Lifesciences rose 1.3 percent on receiving final approval from the U.S.FDA to manufacture Jaythari (Deflazacort) tablets. IRCON soared 4 percent on bagging a work order worth Rs 127.8 crore ...